Novo Nordisk A/S (NYSE:NVO)
| 66.94 BATS BZX Real-Time Price As of 12:32pm ET |  -0.65 / -0.96%Today’s Change | 49.24 Today|||52-Week Range 73.81 | +15.65% Year-to-Date |
Latest NVO News | Press Releases
| Jim Simons' Firm's Top 5 Sells of the 3rd Quarter Nov 19 / GuruFocus News - Paid Partner Content | Gilead (GILD), Novo Nordisk Post Upbeat Data From NASH Study Nov 16 / Zacks.com - Paid Partner Content |
| High-Potential Chinese Biotechs: Hua Medicine, I-MAB and Innovent Biologics Nov 19 / GuruFocus News - Paid Partner Content | The Zacks Analyst Blog Highlights: Facebook, Verizon, Toyota Motor, Novo Nordisk, Applied Materials and General Motors Nov 12 / Zacks.com - Paid Partner Content |
| Novo Nordisk's (NVO) Phase IIIb Study Meets Primary Endpoint Nov 18 / Zacks.com - Paid Partner Content | Top Research Reports for Facebook, Verizon & Toyota Motor Nov 11 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 67.59 |
| Today’s open | 67.24 |
| Day’s range | 66.85 - 67.34 |
| Volume | 637,834 |
| Average volume (3 months) | 1,051,476 |
| Market cap | $119.2B |
Data as of 12:33pm ET, 11/23/2020
Growth & Valuation
| Earnings growth (last year) | -2.68% |
| Earnings growth (this year) | +18.21% |
| Earnings growth (next 5 years) | +10.80% |
| Revenue growth (last year) | +3.34% |
| P/E ratio | 23.8 |
| Price/Sales | 7.53 |
| Price/Book | 18.37 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| SNYSanofi | -0.54 | -1.07% |
| LLYEli Lilly and Co | -3.69 | -2.54% |
| BMYBristol-Myers Squibb | -0.30 | -0.49% |
| AZNAstraZeneca | -1.07 | -1.94% |
Data as of 12:36pm ET, 11/23/2020
Financials
| Next reporting date | February 3, 2021 |
| EPS forecast (this quarter) | $0.57 |
| Annual revenue (last year) | $18.3B |
| Annual profit (last year) | $5.8B |
| Net profit margin | 31.92% |
Profile
Sector Health Technology |
Industry Pharmaceuticals: Major |
No executives to display |
Corporate headquarters Bagsværd, Capital Region |
Forecasts
